Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Subscribe To Our Newsletter & Stay Updated
